Keyword Connections

•  Albert Reynolds
•  Alissa Weaver
•  Andries Zijlstra
•  Dayanidhi Raman

•  florent Elefteriou
•  Irina Kaverina
•  Jin Chen
•  Julie Sterling

•  Mary Zutter
•  Serk In Park

Resources

• No matching connections

Communities

• Beauchamp Laboratory
• Elefteriou Lab
• PMM Lab

Publications

• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
  Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A
  (2012) N Engl J Med 366: 707-14
• Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists. Evidence for an important role of H2 receptors in human vasculature.
  Roberts LJ, Marney SR, Oates JA
  (1979) N Engl J Med 300: 236-8
• Chemotherapy and immunotherapy in metastatic colorectal cancer.
  Pohlmann PR, Mernaugh RL, Goff LW
  (2009) N Engl J Med 360: 2134; author reply 2135-6
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
  Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K
  (2010) Nature 467: 596-9
• Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk.
  Zhang B, Jia WH, Matsuda K, Kweon SS, Matsuo K, Xiang YB, Shin A, Jee SH, Kim DH, Cai Q, Long J, Shi J, Wen W, Yang G, Zhang Y, Li C, Li B, Guo Y, Ren Z, Ji BT, Pan ZZ, Takahashi A, Shin MH, Matsuda F, Gao YT, Oh JH, Kim S, Ahn YO, Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), Chan AT, Chang-Claude J, Slattery ML, Colorectal Transdisciplinary (CORECT) Study, Gruber SB, Schumacher FR, Stenzel SL, Colon Cancer Family Registry (CCFR), Casey G, Kim HR, Jeong JY, Park JW, Li HL, Hosono S, Cho SH, Kubo M, Shu XO, Zeng YX, Zheng W
  (2014) Nat Genet 46: 533-42
• Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis.
  McDonald OG, Li X, Saunders T, Tryggvadottir R, Mentch SJ, Warmoes MO, Word AE, Carrer A, Salz TH, Natsume S, Stauffer KM, Makohon-Moore A, Zhong Y, Wu H, Wellen KE, Locasale JW, Iacobuzio-Donahue CA, Feinberg AP
  (2017) Nat Genet 49: 367-376
• Integrative mathematical oncology.
  Anderson AR, Quaranta V
  (2008) Nat Rev Cancer 8: 227-34
• Differentiated horizontal interneurons clonally expand to form metastatic retinoblastoma in mice.
  Ajioka I, Martins RA, Bayazitov IT, Donovan S, Johnson DA, Frase S, Cicero SA, Boyd K, Zakharenko SS, Dyer MA
  (2007) Cell 131: 378-90
• The Molecular Taxonomy of Primary Prostate Cancer.
  Cancer Genome Atlas Research Network
  (2015) Cell 163: 1011-25
• Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
  Coussens LM, Fingleton B, Matrisian LM
  (2002) Science 295: 2387-92
• Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis.
  McCaffrey LM, Montalbano J, Mihai C, Macara IG
  (2012) Cancer Cell 22: 601-14
• Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming.
  Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schübeler D, van Nimwegen E, Christofori G
  (2013) Cancer Cell 23: 768-83
• Hepsin promotes prostate cancer progression and metastasis.
  Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V
  (2004) Cancer Cell 6: 185-95
• Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors.
  Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, Lechel A, Rudolph KL, Langer R, Slotta-Huspenina J, Bader FG, Prazeres da Costa O, Neurath MF, Meining A, Kirchner T, Greten FR
  (2013) Cancer Cell 23: 93-106
• Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.
  Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM
  (2007) Cancer Cell 12: 559-71
• The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151.
  Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP
  (2008) Cancer Cell 13: 221-34
• The DARC side of metastasis: shining a light on KAI1-mediated metastasis suppression in the vascular tunnel.
  Zijlstra A, Quigley JP
  (2006) Cancer Cell 10: 177-8
• Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.
  Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL
  (2008) Cancer Cell 13: 23-35
• Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.
  Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA
  (2003) Cancer Cell 4: 437-50
• The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis.
  Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW, Keely PJ, Longmore GD
  (2013) Nat Cell Biol 15: 677-87
• TGF-beta helps cells fly solo.
  Matise LA, Pickup MW, Moses HL
  (2009) Nat Cell Biol 11: 1281-4
• Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.
  Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ
  (1999) J Clin Oncol 17: 2541-5
• Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.
  Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA
  (2011) J Clin Oncol 29: 2357-63
• Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
  Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL, American Society of Clinical Oncology, College of American Pathologists
  (2007) J Clin Oncol 25: 5418-25
• Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
  Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC
  (2013) J Clin Oncol 31: 1726-31
• Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
  Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F
  (2005) J Clin Oncol 23: 3502-8
• Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
  Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA
  (2009) J Clin Oncol 27: 3584-90
• [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
  Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD
  (2005) J Clin Oncol 23: 1136-43
• Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
  Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG
  (2003) J Clin Oncol 21: 2059-69
• Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?
  Rothenberg ML, Berlin JD
  (2003) J Clin Oncol 21: 3716-7
• Psychogenic factors in predicting survival of breast cancer patients.
  Jamison RN, Burish TG, Wallston KA
  (1987) J Clin Oncol 5: 768-72
• Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
  Rothenberg ML, LaFleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AB, Coffey RJ
  (2005) J Clin Oncol 23: 9265-74
• Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
  Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP
  (2013) J Clin Oncol 31: 4387-93
• Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial.
  Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, Patterson GA, Inculet RI, Jones DR, Malthaner RA, Cohen RG, Ballman K, Putnam JB, Cote RJ
  (2011) J Clin Oncol 29: 4313-9
• Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
  Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM, Eastern Cooperative Oncology Group
  (2008) J Clin Oncol 26: 5748-54
• Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.
  Rao G, Crispens M, Rothenberg ML
  (2007) J Clin Oncol 25: 2867-72
• Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
  Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE
  (2000) J Clin Oncol 18: 371-5
• Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
  McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB
  (2005) J Clin Oncol 23: 133-41
• Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer.
  Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, Glass EC, Turner RR
  (2000) J Clin Oncol 18: 2553-9